Data Insights

CCAR-168 by AbelZeta for Lupus Nephritis: Likelihood of Approval

CCAR-168 is under clinical development by AbelZeta and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I...

Data Insights

Mesenchymal Stem Cells-Derived Exosomes by AbelZeta for Acute Respiratory Distress Syndrome: Likelihood of Approval

Mesenchymal Stem Cells-Derived Exosomes is under clinical development by AbelZeta and currently in Phase II for Acute Respiratory Distress Syndrome....

Data Insights

CTIL-051 by AbelZeta for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

CTIL-051 is under clinical development by AbelZeta and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to...

Data Insights

CBM-C30.1 by AbelZeta for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

CBM-C30.1 is under clinical development by AbelZeta and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - CBM-C30.1 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

CBM-C30.1 by AbelZeta for Non-Hodgkin Lymphoma: Likelihood of Approval

CBM-C30.1 is under clinical development by AbelZeta and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - CBM-C30.1 in Non-Hodgkin Lymphoma

Data Insights

Gene Therapy to Target MS4A1 for Chronic Lymphocytic Leukemia, Refractory and Relapsed Diffuse Large B-cell Lymphoma by AbelZeta for Non-Hodgkin Lymphoma: Likelihood of Approval

Gene Therapy to Target MS4A1 for Chronic Lymphocytic Leukemia, Refractory and Relapsed Diffuse Large B-cell Lymphoma is under clinical development...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target MS4A1 For Chronic Lymphocytic Leukemia, Refractory And Relapsed Diffuse Large B-cell Lymphoma in Non-Hodgkin Lymphoma